Clinical Trials
11 trialsNCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04474951 2020-07-17
GALENO 1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase NA Unknown
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00003600 2016-07-13
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02781155 2016-05-24
Limiting Chemotherapy Side Effects by Using Moxa
East and North Hertfordshire NHS Trust
Phase 1/2 Unknown
NCT00003538 2014-05-02
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT00022386 2013-07-18
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 4 Completed
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00270166 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00211133 2010-11-30
A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00120692 2007-12-24
Treatment for Patients Suffering From Anemia Due to Chemotherapy
Amgen
Phase 2 Completed